[go: up one dir, main page]

UY29991A1 - Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea - Google Patents

Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea

Info

Publication number
UY29991A1
UY29991A1 UY29991A UY29991A UY29991A1 UY 29991 A1 UY29991 A1 UY 29991A1 UY 29991 A UY29991 A UY 29991A UY 29991 A UY29991 A UY 29991A UY 29991 A1 UY29991 A1 UY 29991A1
Authority
UY
Uruguay
Prior art keywords
phenil
promarms
isopropil
pirimidin
metoxi
Prior art date
Application number
UY29991A
Other languages
English (en)
Inventor
Franzanne Vreeland
Ravi Mysore Shanker
Douglas Alan Lorenz
Susan Deborah Lagreca
Feng Gluo
Tracy Lee Boyden
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY29991A1 publication Critical patent/UY29991A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a compuestos de la fórmula o una sal farmacéuticamente aceptable, profármaco o hidratos de los mismos. La invención también se refiere a composiciones farmacéuticas que contienen los compuestos de fórmula 1 y a métodos para tratar trastornos hiperproliferativos en un mamífero por medio de la ad ministración de los compuestos de fórmula 1.
UY29991A 2005-12-09 2006-12-06 Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea UY29991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74907005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
UY29991A1 true UY29991A1 (es) 2007-07-31

Family

ID=38123252

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29991A UY29991A1 (es) 2005-12-09 2006-12-06 Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea

Country Status (8)

Country Link
AR (1) AR058293A1 (es)
DO (1) DOP2006000271A (es)
GT (1) GT200600496A (es)
NL (1) NL2000337A1 (es)
PE (1) PE20071037A1 (es)
TW (1) TW200733965A (es)
UY (1) UY29991A1 (es)
WO (1) WO2007066189A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143423A1 (en) * 2007-10-19 2009-06-04 Abbott Gmbh & Co. Kg Solid dispersion product containing n-aryl urea-based compound
AU2008313622A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of N-aryl urea-based drugs
JP5819195B2 (ja) * 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
WO2011082273A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
BR112012032248A2 (pt) * 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
PE20190736A1 (es) 2012-06-13 2019-05-23 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN107722012B (zh) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2025015449A (ja) * 2023-07-18 2025-01-30 信越化学工業株式会社 固体分散体用組成物、固体分散体及び固体分散体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives

Also Published As

Publication number Publication date
DOP2006000271A (es) 2007-08-15
PE20071037A1 (es) 2007-11-19
AR058293A1 (es) 2008-01-30
NL2000337A1 (nl) 2007-06-12
GT200600496A (es) 2007-07-17
TW200733965A (en) 2007-09-16
WO2007066189A3 (en) 2008-08-14
WO2007066189A2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
UY29991A1 (es) Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea
ECSP055867A (es) Derivados de pirrolopirimidina
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
CR10027A (es) Nuevos derivados de pirrol fusionado
ECSP014097A (es) Derivados de tiofeno utiles como agentes anticancerosos
CR10636A (es) Inhibidor de quinasa
UY29322A1 (es) Inhibidores de cxcr2
CR10710A (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
ECSP099663A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y métodos para utilizar la misma
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
UY30460A1 (es) Compuestos terapéuticos
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
PA8582101A1 (es) Indoles sustituidos en posicion 2,4
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
AR070661A1 (es) 1,2,4- triazoles trisustituidos
AR057885A1 (es) Acido 1-(1-(2- etoxietil) - 1- etil-7-(4- metilpiridin -2- ilamino)- 1h pirazolo (4,3-d) pirimidin -5- il) piperidina -4- carboxilico y las sales del mismo. composiciones farmaceuticas.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161213